Haemonetics Corporation
HAE
$54.08
-$0.025-0.05%
NYSE
| 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.91% | 3.95% | 8.14% | 9.84% | 9.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.91% | 3.95% | 8.14% | 9.84% | 9.47% |
| Cost of Revenue | -7.58% | -0.99% | 5.35% | 6.67% | 7.00% |
| Gross Profit | 8.07% | 8.10% | 10.50% | 12.62% | 11.64% |
| SG&A Expenses | -0.83% | 1.31% | 5.87% | 9.08% | 14.73% |
| Depreciation & Amortization | 27.42% | 50.67% | 60.21% | 36.83% | 16.64% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.78% | 2.24% | 7.55% | 8.62% | 10.08% |
| Operating Income | 21.59% | 13.18% | 11.25% | 16.79% | 6.13% |
| Income Before Tax | 43.23% | 39.64% | 2.28% | -0.26% | -12.25% |
| Income Tax Expenses | 47.01% | 29.40% | 0.52% | 13.08% | 3.77% |
| Earnings from Continuing Operations | 42.17% | 42.64% | 2.76% | -3.48% | -15.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.17% | 42.64% | 2.76% | -3.48% | -15.87% |
| EBIT | 21.59% | 13.18% | 11.25% | 16.79% | 6.13% |
| EBITDA | 19.29% | 16.11% | 15.41% | 17.42% | 7.59% |
| EPS Basic | 45.80% | 44.10% | 2.55% | -4.07% | -16.21% |
| Normalized Basic EPS | 7.42% | 9.91% | 8.17% | 16.72% | 10.23% |
| EPS Diluted | 47.02% | 44.92% | 3.25% | -3.22% | -15.85% |
| Normalized Diluted EPS | 8.14% | 10.53% | 8.70% | 17.11% | 10.40% |
| Average Basic Shares Outstanding | -2.33% | -0.74% | 0.21% | 0.58% | 0.38% |
| Average Diluted Shares Outstanding | -2.97% | -1.30% | -0.27% | 0.24% | 0.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |